|Bid||18.21 x 800|
|Ask||18.33 x 2200|
|Day's Range||18.18 - 18.47|
|52 Week Range||11.98 - 23.92|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.89|
Alkermes plc (Nasdaq: ALKS) announced today that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m. GMT). During the event, members of Alkermes' senior management and research and development team will discuss the company's research and development strategy in neuroscience and oncology, review clinical data and strategy related to nemvaleukin alfa (ALKS 4230) and highlight the company's earlier stage development programs, including ALKS 1140. The company will also discuss the Value Enhancement Plan announced in December 2020.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb. 24, 2021 at 9:20 a.m. ET (2:20 p.m. GMT). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.